Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Ann Oncol
; 33(7): 743-744, 2022 Jul.
Article
in En
| MEDLINE
| ID: mdl-35595658
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Type:
Article